background : hepatopulmonary syndrome (hps) refers to arterial hypoxemia caused by pulmonary vasodilation, which is a consequence of portal hypertension. hps is associated with increased morbidity and mortality; thus, it is important to diagnose this entity as soon as possible for treatment to be administered. materials and methods: in a cross-sectional study, 40 children (6 months to 14 years ...

The hepatopulmonary syndrome (HPS) develops when pulmonary vasodilatation leads to abnormal gas exchange. However, in human HPS, restrictive ventilatory defects are also observed supporting that the alveolar epithelial compartment may also be affected. Alveolar type II epithelial cells (AT2) play a critical role in maintaining the alveolar compartment by producing four surfactant proteins (SPs,...

BACKGROUND AND AIM The prevalence of hepatopulmonary syndrome (HPS) in the setting of cirrhosis ranges between 4%-47%. We aimed to detect a correlation between heart and lungs findings on contrast-enhanced ultrasound (CEUS)and pulse-oximetry, in order to early detect HPS and thus to improve patients referral to orthotopic liver transplantation(OLT). METHODS We considered at risk for HPS all p...

We report a 70-year-old man with hepatopulmonary syndrome (HPS) in C liver cirrhosis. Hypoxemia worsened markedly, especially on exertion, while the hepatic function was clinically stable. Contrast echocardiography, 99mTc macroaggregated albumin (99mTcMAA) lung scan, and pulmonary angiography were performed. The findings suggested the presence of both intrapulmonary vascular dilatation and subs...

Hepatopulmonary syndrome (HPS) following rat common bile duct ligation results from pulmonary molecular changes that may be influenced by circulating TNF-alpha and increased vascular shear stress, through activation of NF-kappaB or Akt. Increased pulmonary microvascular endothelin B (ET(B)) receptor and endothelial nitric oxide synthase (eNOS) levels contribute to nitric oxide production and th...

A Task Force on Pulmonary-Hepatic Vascular Diseases (PHD), approved and funded by the European Respiratory Society (ERS), was developed by a panel of chest physicians, hepatologists and gastroenterologists during the period 2002–03 and published in 2004 [1]. The major goals of this ERS Task Force on PHD are: (1) to increase awareness of both hepatopulmonary syndrome (HPS) and portopulmonary hyp...

BACKGROUND The hepatopulmonary syndrome (HPS) is defined as the triad of liver disease, arterial deoxygenation, and pulmonary vascular dilatation. The reported prevalence of HPS in cirrhotic patients varies between 4% and 19%, and various threshold values defining arterial deoxygenation have been used and recommended previously. However, it is not known how the prevalence of HPS differs using d...

Background: The hepatopulmonary syndrome (HPS) is defined as the triad of liver disease, arterial deoxygenation, and pulmonary vascular dilatation. The reported prevalence of HPS in cirrhotic patients varies between 4% and 19%, and various threshold values defining arterial deoxygenation have been used and recommended previously. However, it is not known how the prevalence of HPS differs using ...

Hepatopulmonary syndrome (HPS) is a complication of liver cirrhosis and is responsible for chronic hypoxemia and its negative health consequences. The most relevant diagnostic criterion of HPS is evidence of pathological intrapulmonary blood shunting (IPBS). There is still insufficient knowledge about the subclinical forms of HPS. The aim of this study was to determine whether an erect posture ...

Hepatopulmonary syndrome (HPS) is a defective liver-induced pulmonary vascular disorder with massive pulmonary microvascular dilation and excessive proliferation of pulmonary microvascular endothelial cells (PMVECs). Growing evidence suggests that autophagy is involved in pulmonary diseases, protectively or detrimentally. Thus, it is interesting and important to explore whether autophagy might ...